Elie G. Dib, MD, MS, FACP, is a board-certified hematologist–oncologist, researcher, and educator whose career bridges clinical excellence, academic leadership, and cutting-edge work in cancer immunogenomics. He serves as a Lecturer at Johns Hopkins University, where he teaches in the MS in Bioinformatics, MS in Biotechnology, and MS in Individualized Genomics and Health programs at the Center for Biotechnology Education. His teaching integrates clinical oncology with molecular science, reflecting his passion for advancing precision medicine and training the next generation of cancer researchers.
In clinical practice, Dr. Dib is based in the Ann Arbor metropolitan area of Michigan, where he specializes in caring for patients with hematologic malignancies and solid tumors. His expertise spans lymphoma, multiple myeloma, leukemia, myelodysplastic syndromes, and bone marrow disorders, as well as breast cancer, lung cancer, melanoma, gastrointestinal cancers, head and neck cancers, sarcomas, and genitourinary malignancies. He is particularly committed to the application of immunotherapy, targeted therapy, and genomic-driven treatment strategies, areas that have shaped both his clinical and research endeavors.
Dr. Dib is deeply involved in national oncology leadership. He serves as a Member of the National Cancer Institute’s Genitourinary Cancers Steering Committee and as Community Vice Chair of the Immuno-Oncology Committee for the Alliance for Clinical Trials in Oncology, where he also co-chairs national clinical trials. He contributes to the ASCO TAPUR Molecular Tumor Board, helping guide precision oncology decision-making across the United States, and serves as an Associate Editor for the ASCO Self-Education Program.
Within Michigan, Dr. Dib plays a vital role in shaping oncology training and clinical research. He is the Associate Program Director for the Hematology–Oncology Fellowship at St. Joseph Mercy Hospital and a Deputy Principal Investigator with the Michigan Cancer Research Consortium through the NCI Community Oncology Research Program (NCORP), advancing clinical trials access for community-based patients.
Dr. Dib’s scientific foundation was built at the University of Rochester, followed by advanced postgraduate education at Harvard Medical School, where his research focused on cancer immunotherapy and tumor genomics. He further specialized his training by earning a Master of Science in Individualized Genomics and Health from Johns Hopkins University, reinforcing his commitment to precision oncology.
He has authored influential publications in JCO Precision Oncology, Clinical Genitourinary Cancer, and other major journals. His featured works include analyses of HER2-directed therapies in lung cancer (2023), CDK4/6 inhibition in CDKN2A-altered tumors (2020), and immunotherapy response in treatment-resistant prostate cancer (2019).
A Fellow of the American College of Physicians (FACP), Dr. Dib is widely admired for his ability to unite research, education, and compassionate patient care. Through his national leadership roles, contributions to precision oncology, and dedication to mentorship, he continues to shape the evolving landscape of cancer treatment and cancer genomics.
Inspiring Progress in Cancer Care: Elie Dib Recognized by NCI for Clinical Trial Excellence
He is a Member of the Editorial Board of OncoDaily.
Contact: [email protected]